Lung Cancer Biomarker Testing ECHO Year 3
December 2023 - May 2024
Despite an unprecedented deployment of new effective treatment options for non-small cell lung cancer (NSCLC) that targets specific biomarkers, many patients face enormous challenges obtaining comprehensive biomarker testing. Participating health systems will gain the knowledge to address common barriers that exist within their cancer teams and institutions that preclude them from implementing NSCLC biomarker testing. This program has six hour-long sessions between January and May 2024.